NYSE - Delayed Quote • USD
ADC Therapeutics SA (ADCT)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 7:30 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | -0.56 | -0.55 | -2.15 | -1.78 |
| Low Estimate | -0.66 | -0.65 | -2.53 | -2.2 |
| High Estimate | -0.48 | -0.45 | -1.72 | -1.51 |
| Year Ago EPS | -0.74 | -0.58 | -2.94 | -2.15 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 5 |
| Avg. Estimate | 18.21M | 19.54M | 80.95M | 94.25M |
| Low Estimate | 17.6M | 18.2M | 75.1M | 75.9M |
| High Estimate | 18.85M | 20.7M | 92M | 108M |
| Year Ago Sales | 18.99M | 41.55M | 69.56M | 80.95M |
| Sales Growth (year/est) | -4.10% | -53.00% | 16.40% | 16.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.67 | -0.46 | -0.63 | -0.5 |
| EPS Actual | -0.74 | -0.58 | -0.58 | -1.03 |
| Difference | -0.07 | -0.12 | 0.05 | -0.53 |
| Surprise % | -10.40% | -26.10% | 7.90% | -106.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.56 | -0.55 | -2.15 | -1.78 |
| 7 Days Ago | -0.56 | -0.55 | -2.15 | -1.78 |
| 30 Days Ago | -0.54 | -0.53 | -2.08 | -1.71 |
| 60 Days Ago | -0.47 | -0.46 | -1.92 | -1.61 |
| 90 Days Ago | -0.49 | -0.42 | -1.76 | -1.47 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | ADCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 24.30% | -- | -- | 0.40% |
| Next Qtr. | 5.20% | -- | -- | 9.90% |
| Current Year | 26.90% | -- | -- | 4.30% |
| Next Year | 17.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 15.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/15/2024 |
| Reiterates | Guggenheim: Buy | 4/5/2024 |
| Initiated | Guggenheim: Buy | 3/28/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 3/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/26/2024 |
Related Tickers
ADAP Adaptimmune Therapeutics plc
1.1400
+12.87%
STRO Sutro Biopharma, Inc.
3.7200
-1.33%
DTIL Precision BioSciences, Inc.
10.23
+5.68%
MRSN Mersana Therapeutics, Inc.
3.2100
+1.90%
KPTI Karyopharm Therapeutics Inc.
1.0900
-3.54%
KURA Kura Oncology, Inc.
18.73
+2.97%
BCAB BioAtla, Inc.
2.2400
+2.75%
LVTX LAVA Therapeutics N.V.
2.9800
+4.56%
PSTX Poseida Therapeutics, Inc.
2.1600
+0.23%
BDTX Black Diamond Therapeutics, Inc.
5.01
-0.20%